Drug Makers Confront Headwinds In 2026, But MFN Doesn’t Seem Like A Big One

 
• By Jessica Merrill
  
(Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Drug Pricing

More from Scrip